Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinun complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 3113-3117

  Di Blasi, Patrizia ^a   Bernareggi, Alberto ^a   Beggiolin, Gino ^a   Piazzoni, Laura ^a   Menta, Ernesto ^a   Formento, Maria Luisa ^a  

^a Boehringer Ingelheim Italia SpA   (Italy)

Author keywords

DNA platinum binding; Drug uptake; Platinum complexes

Indexed keywords

BBR 3464; CISPLATIN; DNA; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG DNA BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG UPTAKE; LEUKEMIA CELL; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; KINETICS; LEUKEMIA L1210; MICE; ORGANOPLATINUM COMPOUNDS; SENSITIVITY AND SPECIFICITY;

EID: 0031812465     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia F M: Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 types of malignancies. Cancer Research 53: 3694-3699, 1993.
2. Klastersky J, Sculier J P, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P and Paesmans M: A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer. European Organization for research and treatment of cancer protocol 07861. Journal of Clinical Oncology 8: 1556-1562, 1990.
3. 2]. Science 218: 1075-82, 1982.
4. Roberts JJ and Pera MF: DNA as a target for anticancer coordination compounds. In: S.J Lippard, ed. Platinum gold and other metal chemotherapeutic agents: chemistry and biochemistry. Washington DC: American Chemical Society 3-25, 1983.
5. Gately DP and Howell SB: Cellular accumulation of the anticancer agent cisplatin: A review British Journal Cancer 67: 1171-1176, 1993.
6. Prestayko AW, D'Aoust JC, Issell BF et al: Cisplatin (cis-diammine dichloro platinum II). Cancer Treat Rev 6: 17-39, 1979.
7. Andrews PA, Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1990.
8. Farrell N, Qu Y, Kasparkova J, Brabec V, Valsecchi M, Menta E, Di Domenico R, Conti M, Da Re G, Lotto A, Spinelli S: Chemical studies and DNA binding of charged polynuclear platinum complexes. Proc Annu Meet Am Assoc Cancer Res 38: 310, 1997. (abstract)
9. Giuliani FC, Beggiolin G, Piazzoni L, Formento ML, Di Blasi P, Farrell N, Kelland L, Caserini C, Perego P, Supino R and Zunino F: Pattern of cellular sensitivity to BBR 3464, a novel trinuclear platinum complex, in human tumor cell lines: Lack of cross-resistance with cisplatin. Proc Annu Meet Am Assoc Cancer Res 38: 310, 1997 (abstract)
10. Hrubisko M, McGown AT and Fox BW: The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. Biochemical Pharmacology 45: 253-256, 1993.
11. Richon VM, Schulte N and Eastman A: Multiple mechanisms of resistance to cis-Diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Research 47: 2056-2061, 1987.
12. Kelley SL, Basu A,Teicher BA, Hacker MP, Hamer DH and Lazo JS: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815, 1988.
13. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF and Hamilton TC: Role of platinum-DNA adduct formation and removal of cisplatin resistance in human ovarian cancer cell lines. Biochemical Pharmacology 47: 689-697, 1994
14. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Meth 65: 55-63, 1983.
15. Fritsch EF, Sambrook J, Maniatis T: Molecular Cloning a laboratory manual. Second edition. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press 1989.
16. Reed E, Sauerhoff S and Poirier MC: Quantitation of Platinum-DNA Binding After Therapeutic Levels of drug exposure. A novel use of graphite furnace. Atomic Spectroscopy 9: 93-95, 1988
17. Beach L et al: In Anaytical methods for graphite tube atomizer (E. Rothery eds) Mulgrave, Victoria, Australia 85: 54, 1988.
18. Farrell N: Nonclassical Platinum Antitumor Agents: perspectives for design and development of new drugs complementary to cisplatin. Cancer Investigation 11: 578-589, 1993.
19. Kido Y, Khokhar AR and Siddik ZH: Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anti-Cancer Drugs 4: 251-258, 1993.
20. Manzotti C, Pratesi G, Zunino F, Di Domenico R, Sala F, Piazzoni L, Bernareggi A, Giuliani FC and Tognella S: BBR 3464 a novel charged trinuclear Platinum complex for treatment of cisplatin insensitive tumor. Tumori, Suppl 1 83: 134, 1997. (abstract)